뒤로
Prokidney Corp(PROK) 가격
PROK 주가 차트
PROK 수입
Prokidney Corp
$2.29
5.04%
$0.1
종가: Jan 16, 16:00:00 GMT-5
$2.24
-2.18%
$-0.04
애프터마켓: Jan 16, 20:00:00 GMT-5
주요 통계
이전 종가
$2.18
시가
$2.21
일일 범위
$2.16 - $2.31
52주 범위
$0.46 - $7.13
거래량
1.5M
평균 거래량
1.3M
EPS(TTM)
-0.54
배당수익률
--
시가총액
$673.8M
PROK란 무엇인가요?
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.